Recent Zofran Lawsuit Claims Allege Children Suffered Birth Defects As A Result of Anti-Nausea Medication

Print

Wright & Schulte Is Representing Clients In Zofran Lawsuits Alleging Use Of Zofran During Pregnancy Caused Such Birth Defects As Congenital Heart Defects, Cleft Palate, Cleft Lip And Musculoskeletal Defects.

Zofran-Birth-Defects-Lawsuit-Wright-and-Schulte-LLCZofran lawsuit claims continue to contend the use of the anti-nausea drug Zofran during pregnancy lead to birth defects with filing of recent complaint Wright & Schulte LLC, who is currently representing clients in birth defect lawsuits has learned a recent complaint was filed on behalf of two Louisiana mothers whose children developed serious birth defects purportedly as a result of prenatal exposure to Zofran. One mother was prescribed Zofran in her first trimester of pregnancy to treat morning sickness and her child was born on July 15, 2010 with atrial septal defect (also known as “hole in the heart”), perimembranous ventricular septal defect (VSD), which required surgery to correct, and other congenital heart defects. The second mother took Zofran and her child was born on August 9, 2005 and was diagnosed soon after birth with accelerated ventricular arrhythmia, a serious heart defect which nearly caused the baby to die shortly after birth, according to the complaint. The Zofran lawsuit claims purport that GlaxoSmithKline (GSK), the maker of Zofran, knew about the risks of unborn children developing serious birth defects but illegally marketed Zofran as safe to treat pregnancy-induced nausea in pregnant women. (Case No. 6:15-cv-01815, U.S. District Court, Western District of Louisiana)

“This jointly filed Zofran lawsuit claims show how children are continuing to experience birth defects due to Zofran,” says Wright & Schulte LLC, a law firm that aggressively represents families whose children have been injured by the side effects of harmful drugs. “The plaintiffs in Zofran lawsuits all commonly say that physicians would not have prescribed the anti-nausea drug to treat morning sickness and pregnant women would not have taken the drug had GlaxoSmithKline disclosed the birth defects risk associated with Zofran.”

As stated in the Zofran birth defect complaint, Zofran is an anti-emetic drug approved by the U.S. Food and Drug Administration (FDA) in 1991 to treat severe nausea in cancer patients undergoing chemotherapy and radiation treatments. According to the complaint, this remains the only FDA-approved use for Zofran. By 1992, GSK had a “multitude of evidence” linking Zofran to birth defects, including a study that found that Zofran crosses the human placenta barrier and exposes unborn children to substantial concentrations of the drug, the Zofran lawsuit says. The Zofran birth defects complaint purports that GSK never disclosed this information to pregnant women or their physicians. (Case No. 6:15-cv-01815, U.S. District Court, Western District of Louisiana)

Court documents indicate that GSK was cited by the U.S. Department of Justice (DOJ) for illegally promoting Zofran and its other drugs for off-label use. According to the DOJ, the company agreed to pay $3 billion to resolve civil and criminal claims, including promoting Zofran as a drug to treat morning sickness in pregnant women without receiving approval from the FDA. The DOJ complaint also accused the company of promoting Zofran to expectant mothers and their physicians without telling them about the risk of taking the drug during pregnancy, and offered kickbacks to health care professionals who promoted and prescribed Zofran. The DOJ commented that GSK’s case was the largest health care fraud settlement in U.S. history and the largest payment ever by a drug company.

The law firm notes that the Louisiana mothers’ lawsuit is similar to other Zofran complaints being filed on behalf of families whose children were born with serious and dangerous birth defects such as cleft lip, cleft palate, heart murmur, heart defects, atrial septal defect (hole in the heart), musculoskeletal defects and other abnormalities. The Louisiana mothers’ complaint said that they did not know at the time of their children’s births the “tortious nature of the conduct causing the alleged injuries,” until a short time before filing their complaint. According to the lawsuit, the plaintiffs were prevented from discovering this information sooner because GSK misrepresented to the public and to the medical profession that Zofran is safe for use in pregnancy. (Case No. 6:15-cv-01815, U.S. District Court, Western District of Louisiana)

About Wright & Schulte LLC

Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Zofran lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:
Wright & Schulte LLC
865 S. Dixie Dr.
Vandalia, Ohio 45377
1-800-399-0795
www.yourlegalhelp.com

This entry was posted in Wright & Schulte Lawsuit News. Bookmark the permalink.